Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jun 23, 2020
TickeronGET DAILY SIGNALS
Aurora Cannabis (ACB, $13.73) to layoff 700 workers, close 5 facilities, and take $60 million charge

Aurora Cannabis (ACB, $13.73) to layoff 700 workers, close 5 facilities, and take $60 million charge

Aurora Cannabis announced that it was retrenching about 700 employees, and closing five production facilities. It is also taking a $60 million charge for the quarter ending June 30.

The layoffs include  an approximate 25% reduction in Aurora's SG&A [selling, general and administrative] staff, most with immediate effect, and an approximate 30% reduction in production staff over the next two quarters, according to the cannabis company’s statement.

Aurora plans to shutter operations at five facilities over the next two quarters ,in order to orient itself more towards production and manufacturing at the company's “larger scale and highly efficient sites”, as indicated in the company’s statement.

The company expects to record production asset impairment charges of up to $60 million for Q4 2020. It also expects to record a charge of up to $140 million in the carrying value of certain inventory.

Tickeron's AI-powered scorecard rates Aurora Cannabis a STRONG SELL.

ACB enters a Downtrend because Momentum Indicator dropped below the 0 level on June 05, 2020

This indicator signals that ACB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 72 of 84 cases where ACB's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 86%.

Current price $13.65 crossed the support line at $13.19 and is trading between $14.63 resistance and $13.19 support lines. Throughout the month of 05/20/20 - 06/22/20, the price experienced a +8% Uptrend. During the week of 06/15/20 - 06/22/20, the stock enjoyed a +4% Uptrend growth.

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator appears to be shifting from an Uptrend to a Downtrend. In 24 of 40 cases where ACB's RSI indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 60%.

The Moving Average Convergence Divergence (MACD) crossed below the signal line. In 34 of 42 cases where ACB's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 81%.

Bullish Trend Analysis

The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 219 of 266 cases, the price rose further within the following month. The odds of a continued Uptrend are 82%.

The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 33 of 39 cases where ACB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 59%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.69.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.55) is normal, around the industry mean (0.93). P/E Ratio (0.00) is within average values for comparable stocks, (29.45). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (115.92). Dividend Yield (0.00) settles around the average of (1.00) among similar stocks. P/S Ratio (4.63) is also within normal values, averaging (10.69).

The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

Related Ticker: ACB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for ACB turns positive, indicating new upward trend

ACB saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 72 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ACB just turned positive on November 03, 2026. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.

ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ACB crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +24.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 180 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 77 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Bearish Trend Analysis

The 10-day RSI Indicator for ACB moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 17 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ACB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.629) is normal, around the industry mean (6.379). P/E Ratio (-2.701) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 8%. XERS experienced the highest price growth at 58%, while ANIK experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was 9% and the average quarterly volume growth was -19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a licensed producer of medical marijuana in Canada

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
90B Street SW
Phone
+1 855 279-4652
Employees
1028
Web
https://www.auroramj.com
Interact to see
Advertisement
BZ dropped sharply, sliding from a $16.72 prior close to $13.48 (-19.38%), with the decline beginning in premarket and deepening into the early regular session. No verified company-specific news or fundamental catalyst was issued; the fall tracked a broad China ADR selloff (the Nasdaq Golden Dragon index slid more than 2%), but that alone is too small to explain a ~20% drop — the stock's Hong Kong listing fell only -2.6%.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.